Drug intelligence / Profile preview

KD2504

Development stage: Preclinical
Lead developer: Kadmon
Modality: Small Molecules

Overview

KD2504 is an improved new drug (incrementally modified drug) currently in the discovery stage of development by Kyungdong Pharmaceutical for the treatment of diabetes. Within the South Korean regulatory framework, an 'improved new drug' (개량신약) typically refers to a therapeutic agent that has been modified from an existing approved drug to provide enhanced safety, efficacy, or patient convenience, such as through a new formulation, salt, or combination. KD2504 is identified as a small molecule project aimed at addressing glycemic control in diabetic patients.

Beyond the preview

Go deeper on KD2504.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KD2504.

Explore the full profile